-+ 0.00%
-+ 0.00%
-+ 0.00%
Amneal's Adcomfo Wins European Commission Approval
Share
Listen to the news
Amneal's Adcomfo Wins European Commission Approval
  • European Commission grants marketing authorization for Amneal Pharmaceuticals' Adcomfo (omalizumab), a biosimilar to Xolair.
  • The U.S. application for the proposed Xolair biosimilar remains under FDA review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171605PRIMZONEFULLFEED9879850) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending